IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II drugs for Hepatocellular Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMA-203CD8’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMA-203CD8 is under development for the treatment of multiple solid tumors including uveal melanoma, synovial sarcoma, hepatocellular carcinoma and head and neck cancer. The drug candidate consists of IMA203-engineered T cells targeting PRAME co-transduced with CD8αβ T cell co-receptor that plays an important role during T cell antigen recognition and T cell activation. The therapeutic candidate is developed based on ACTengine platform technology.
Immatics is a biopharmaceutical company focused on the development of T cell immunotherapies to fight against cancer. Immatics is headquartered in Tuebingen, Germany.
For a complete picture of IMA-203CD8’s drug-specific PTSR and LoA scores, buy the report here.